Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization by Peterson, RL et al.
Contents lists available at ScienceDirect
Contemporary Clinical Trials Communications
journal homepage: www.elsevier.com/locate/conctc
Comparison of an ordinal endpoint to time-to-event, longitudinal, and
binary endpoints for use in evaluating treatments for severe inﬂuenza
requiring hospitalization
Ross L. Petersona,*, David M. Vocka, Abdel Babikerb, John H. Powers IIIc, Sally Hunsbergerd,
Brian Anguse, Armando Paezf, James D. Neatona, for the INSIGHT FLU-IVIG study group
aUniversity of Minnesota School of Public Health, Division of Biostatistics, Minneapolis, MN, USA
bMRC Clinical Trials Unit at University College London, London, UK
c Collaborative Clinical Research Branch (CCRB), National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
d Biostatistics Research Branch (BRB), National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
eNuﬃeld Department of Medicine, Oxford University, Oxford, UK
fDivision of Infectious Diseases, Baystate Medical Center, University of Massachusetts Medical School – Baystate, Springﬁeld, MA, USA
A R T I C L E I N F O
Keywords:
Clinical trials
Endpoints
Outcome assessments
Proportional odds model
Statistical power
A B S T R A C T
Background/aims: The Food and Drug Administration recommends research into developing well-deﬁned and
reliable endpoints to evaluate treatments for severe inﬂuenza requiring hospitalization. A novel 6-category or-
dinal endpoint of patient health status after 7 days that ranges from death to hospital discharge with resumption
of normal activities is being used in a randomized placebo-controlled trial of intravenous immunoglobulin (IVIG)
for severe inﬂuenza (FLU-IVIG). We compare the power of the ordinal endpoint under a proportional odds model
to other types of endpoints as a function of various trial parameters.
Methods: We used closed-form analysis and empirical simulation to compare the power of the ordinal endpoint
to time-to-event, longitudinal, and binary endpoints. In the simulation setting, we varied the treatment eﬀect
and the distribution of the placebo group across the follow-up period with consideration of adjustment for
baseline health status.
Results: In the analytic setting, ordinal endpoints of high granularity provided greater power than time-to-event
endpoints when most patients in the placebo group had either naturally progressed to the category of hospital
discharge by day 7 or were far from hospital discharge on day 7. In the simulation setting, adjustment for
baseline health status universally raised power for the proportional odds model. Across diﬀerent placebo group
distributions of the ordinal endpoint regardless of adjustment for baseline health status, only time-to-event
endpoints yielded higher power than the ordinal endpoint for certain treatment eﬀects.
Conclusions: In this case study, the FLU-IVIG ordinal endpoint provided greater power than time-to-event,
binary, and longitudinal endpoints for most scenarios of the treatment eﬀect and placebo group distribution,
including the target population studied for FLU-IVIG. The ordinal endpoint was only surpassed by the time-to-
event endpoint when many patients in the placebo group were on the cusp of hospital discharge on day 7 and the
follow-up period for the time-to-event endpoint was extended to allow for additional events. Our general ap-
proach for evaluating the power of several potential endpoints for an inﬂuenza trial can be used for designing
other inﬂuenza trials with diﬀerent target populations and for other trials in other disease areas.
1. Introduction
Among patients with severe inﬂuenza requiring hospitalization, no
trial has demonstrated substantial clinical eﬃcacy of an antiviral drug
[1]. The United States Food and Drug Administration (FDA) re-
commends that primary endpoints in randomized controlled trials
evaluating new treatments for patients hospitalized with inﬂuenza in-
clude any of the following measures: clinical symptoms, duration of
hospitalization, time-to-normalization of vital signs, requirements for
supplemental oxygen, and mortality. In this setting, FDA guidance re-
commends research into developing well-deﬁned and reliable endpoints
that have clinically meaningful outcomes for patients [1].
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Following a successful pilot study of intravenous hyperimmune
immunoglobulin (IVIG) [2], the International Network for Strategic
Initiatives in Global HIV Trials (INSIGHT) launched a placebo-con-
trolled trial of IVIG (FLU-IVIG) to evaluate its eﬃcacy in hospitalized
inﬂuenza patients (NCT02287467) [3]. A 6-category ordinal scale of
patient health status measured 7 days after randomization serves as the
primary endpoint for FLU-IVIG. The ordinal endpoint draws from both
observed and self-reported outcome assessments to construct categories
ranked in subsequent order of patient health status. A recent report by a
working group from the U.S. Department of Health and Human Services
advocates the use of an ordinal endpoint like the one in FLU-IVIG [4].
Two other randomized trials are using an ordinal scale as either the
primary or a secondary endpoint (NCT02572817 & NCT03376321)
[5,6].
Many factors must be considered when selecting an endpoint for a
trial, including clinical relevance, potential bias in ascertainment, and
statistical power. In a previous paper, we examined a number of design
assumptions that may aﬀect power for the FLU-IVIG ordinal endpoint
under the pre-speciﬁed proportional odds model, including deviations
from proportional odds, misclassiﬁcation between the subjective cate-
gories of oxygen use or not and discharged or not, number of categories,
and the anticipated distribution of the ordinal endpoint in the placebo
group [7]. In this paper, we compare the power of the ordinal endpoint
to other clinically relevant endpoints that were also considered, in-
cluding time-to-event, longitudinal, and binary endpoints.
2. Methods
2.1. The INSIGHT FLU-IVIG trial
The FLU-IVIG study is a multicenter, double-blind randomized trial
comparing IVIG versus placebo in hospitalized patients with locally
conﬁrmed inﬂuenza A or B who have a National Early Warning Score of
two or higher [8]. Patients receive IVIG or placebo in addition to
standard of care treatment. The primary endpoint for FLU-IVIG is the
following 6-category ordinal outcome evaluated 7 days after randomi-
zation:
1) death;
2) intensive care unit (ICU) hospitalization;
3) non-ICU hospitalization, requiring supplemental oxygen;
4) non-ICU hospitalization, not requiring supplemental oxygen;
5) discharged from the hospital but unable to resume normal activities;
6) discharged from the hospital with resumption of normal activities.
The categories were deﬁned to delineate clinically relevant change
in patient health status due to IVIG. Day 7 was chosen for evaluation
because a pilot study had established that diﬀerences in inﬂuenza an-
tibody titer levels between IVIG and placebo were highest in the ﬁrst
few days following randomization [2]. The ordinal endpoint was
chosen over a binary endpoint (e.g., proportion of patients discharged
by day 7) because it was thought to provide more power and clinical
information about patient recovery. Note that the ordinal endpoint ig-
nores patient health trajectory across follow-up (e.g., hospitalized pa-
tients are counted as equal to re-admitted patients), only evaluating
status on day 7.
The FLU-IVIG protocol speciﬁes that the estimated odds ratio from
ﬁtting a proportional odds cumulative logistic model will be used to
evaluate the eﬀect of IVIG. Under the proportional odds assumption of
the model, the odds ratios for any of the ﬁve better versus worse di-
visions of the ordinal endpoint (e.g., discharged versus hospitalized or
dead) are constant. That is, the eﬀect of IVIG is no more likely to beneﬁt
patients in one category versus another. Even if the proportional odds
assumption is violated, the estimated odds ratio is still a valid measure
of treatment eﬃcacy for hypothesis testing and can be interpreted as
the average shift across the ordinal endpoint due to IVIG, or
alternatively as the odds of having a more favorable outcome due to
IVIG compared to placebo. Note that the estimated odds ratio is not the
arithmetic mean of the odds ratio for every possible binary division of
the ordinal endpoint but is instead a nonlinear function of the prob-
abilities of each category of the ordinal endpoint in the placebo and
IVIG groups. The score test of the odds ratio is equivalent to the
Wilcoxon rank-sum test [9].
With consideration for the anticipated distribution of the ordinal
endpoint in the placebo group, the FLU-IVIG trial had a sample size of
320 patients to detect an odds ratio of 1.77 with 80% power at the 0.05
(two-sided) level of signiﬁcance. An odds ratio greater than 1 indicates
a more favorable outcome due to IVIG.
2.2. Analytic comparison of ordinal endpoint to time-to-event endpoint
We analytically compare the power of an ordinal endpoint to a time-
to-event endpoint both derived from the same information. For con-
creteness, we refer to the time-to-event endpoint as time-to-hospital
discharge, where deaths are censored at the end of follow-up and ﬁrst
hospital discharge counts as the event. The power for most hypothesis
tests at the 0.05 (two-sided) level of signiﬁcance is approximately equal
to:
≅ − + cPower Φ( 1.96 )
where Φ denotes the cumulative density function of the standard
normal distribution and c is the non-centrality parameter which varies
based on the type of endpoint chosen and the data generating me-
chanism.
We assume that time-to-hospital discharge follows an accelerated
failure time (AFT) model with an exponential distribution and constant
hazard ratio between treatment groups [10]. The AFT model assumes
that the treatment proportionally increases or decreases the quantiles
(e.g., median) of the duration of hospitalization. The non-centrality
parameter for the AFT model, ca, is given by (see supplementary ma-
terial for derivation):
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where n denotes the total sample size assuming equal randomization to
both groups, log denotes the natural logarithm, and pit denotes the
probability of discharge by the end of follow-up (i.e., categories 5 and 6
of the ordinal endpoint combined) for the ith randomized group (0
denotes placebo, 1 denotes treatment) assuming a follow-up period of t
days. We assume the same follow-up period for all patients because in
inﬂuenza trials which motivate this work, follow-up is typically short
and endpoints such as survival and hospital discharge are frequently
assessed with very little missing data. Because the FLU-IVIG trial pro-
tocol expects minimal missing data on day 7 and time-to-hospital dis-
charge is easily recorded, we assumed no missing data in both the
analytic and simulation settings.
We assume that the ordinal endpoint follows a proportional odds
model, as speciﬁed in the FLU-IVIG trial. For the proportional odds
model, the non-centrality parameter, cp, under the proportional odds
assumption on day 7 is provided by Whitehead [11] and is approxi-
mately equal to:
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where q‾i denotes the average categorical probability between both
randomized groups for the ith category of an ordinal endpoint with k
categories, and the fraction =−− 1.77
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from FLU-IVIG. The term
− ∑= q1 ‾i
k
i1
3 measures the granularity of the ordinal endpoint with
larger values indicating an ordinal endpoint whose category propor-
tions are more evenly spread. For example, assume that we have an
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ordinal endpoint with three categories. If patients in the placebo group
are evenly spread about the categories with proportions (1/3, 1/3, 1/3),
and the distribution of patients in the treatment group meets propor-
tional odds (odds ratio= 1.77 from FLU-IVIG) with category propor-
tions (0.22, 0.31, 0.47), then − ∑ == q1 ‾ 0.88i
k
i1
3 . Conversely, if patients
in the placebo group tend to fall towards the last category with (1/10,
1/10, 4/5), and the treatment group again meets proportional odds
(odds ratio= 1.77) with (0.06, 0.06, 0.88), then − ∑ == q1 ‾ 0.41i
k
i1
3 .
Because both non-centrality parameters are proportional to n , this
implies that relative comparisons of the two models according to power
do not depend on sample size for suﬃciently large n. We compared the
power of both endpoints according to diﬀerent values of − ∑= q1 ‾i
k
i1
3 for
the ordinal endpoint and diﬀerent follow-up periods for the time-to-
event endpoint. We varied − ∑= q1 ‾i
k
i1
3 as it measures the granularity of
the ordinal endpoint, which is what a trial designer would want to
maximize (e.g., by splitting or collapsing categories to be more evenly
spread) to raise power. We ﬁxed follow-up at day 7 for the ordinal
endpoint in accordance with the FLU-IVIG trial and because in a trial
with longer follow-up than 7 days, the two hospital discharge categories
may be more diﬃcult to ascertain. We extended the follow-up period of
the time-to-event endpoint from 7 to 14 days to allow for more time for
the event of hospital discharge to occur. Thus, we aimed to make a
comparison between the ordinal and time-to-event endpoints under
follow-up periods considered optimal for each. For both endpoints, we
additionally varied the probability of discharge by day 7 (p07) as a
measure of the underlying risk of the population enrolled in the study.
All other factors (e.g., treatment eﬀect odds ratio of 1.77) were held
constant. Note that we assume that hospital discharge constitutes at
least one category of the ordinal endpoint; thus, values of − ∑= q1 ‾i
k
i1
3
below − +( )1 p p2 307 17 are not possible.
2.3. Simulation comparison of ordinal endpoint to other endpoints
Closed form expressions for (approximate) power only exist for a
small number of endpoints. Furthermore, these expressions typically
assume that the analysis model is consistent with the data generating
mechanism. To broaden the scope of our study, we used simulation to
compare the ordinal endpoint to other types of endpoints for data that
does not follow a constant hazard ratio between treatment groups. We
considered six diﬀerent endpoints each evaluated on day 7, the pre-
speciﬁed time point for FLU-IVIG:
• E1: Proportion of patients hospitalized or dead on day 7.
• E2: Proportion of patients moving to less severe categories from day
0 to day 7.
• E3: Winners versus losers between IVIG and placebo on day 7.
• E4: Day 7 ordinal endpoint.
• E5: Longitudinal measures of the ordinal endpoint over days 1–7 of
follow-up.
• E6: Time-to-ﬁrst hospital discharge.
We considered seven models to ﬁt to these six endpoints. We ﬁtted a
simple logistic regression model to both E1 and E2, but given that E2
compares patient status for two diﬀerent time points, we refer to its
ﬁtted model as the sliding dichotomy [12]. The endpoint E3 considers
all possible comparisons of patients in the IVIG group to those in the
placebo group according to their given ordinal endpoint category on
day 7 [13]. The summary measure for this endpoint, called the win
ratio, calculates the number of comparisons of greater health status for
IVIG relative to placebo (wins) divided by the number of comparisons
of worse health status (losses). Without any stratiﬁcation, the win ratio
performs similar to the well-known nonparametric Wilcoxon rank-sum
test [14].
We ﬁtted the proportional odds model to E4 and a longitudinal
ordinal outcome model to E5 using generalized estimating equations
assuming an independent working correlation matrix [15]. The long-
itudinal ordinal outcome model includes a term for treatment group,
day of assessment (treated as a continuous variable), and day by
treatment group interaction to model the distributions of the ordinal
endpoint in both randomized groups over days 1–7 of follow-up. The
day by treatment group interaction captures the treatment eﬀect as the
average multiplicative change in the odds ratio from the proportional
odds model across days. For example, if the treatment eﬀect pro-
portionally increases by day up to an odds ratio of 1.77 on day 7, then
the coeﬃcient for the day by treatment group interaction would be
1.085 such that 1.0857=1.77.
We ﬁtted both the Cox proportional hazards model and the AFT
model to E6 [16]. Across the follow-up period, the Cox model calculates
the hazard ratio of hospital discharge between groups. To allow for
more ﬂexibility in modeling time-to-hospital discharge for the AFT
model, we assumed a Weibull distribution in addition to an exponential
distribution. All seven models with their corresponding six endpoints
are displayed in Table 1. In addition to models which only include the
treatment eﬀect, we considered models which adjusted for baseline
health status. Baseline health status was deﬁned as which of the three
categories the patient was in at enrollment (i.e., ICU; hospitalized, not
in ICU, on oxygen; and hospitalized, not in ICU, not on oxygen). For the
win ratio, we stratiﬁed comparisons between randomized groups ac-
cording to baseline health status.
To generate longitudinal data comparable to the data that was ex-
pected in the FLU-IVIG trial, we used data from a cohort study of
Table 1
Models ﬁtted to endpoints for the simulated data.
Model Endpoint Endpoint Variable
Type
Coeﬃcient Interpretation
Simple Logistic E1: Proportion of patients hospitalized or
dead on day 7
Binary Odds ratio of discharged from the hospital versus not
discharged on day 7
Sliding Dichotomy E2: Proportion of patients moving to less
severe categories from day 0 to day 7
Binary Odds ratio of moving versus not moving to a less severe
category from day 0 to day 7
Win Ratio E3: Winners versus losers between IVIG
and placebo on day 7
Binary For all possible comparisons of patients in IVIG versus placebo,
the number of IVIG winners divided by the number of IVIG
losers
Proportional Oddsa E4: Day 7 ordinal endpoint Ordinal Average odds ratio of being in a less versus more severe
category on day 7
Longitudinal Ordinal Outcome E5: Distribution of the ordinal endpoint
over the seven days of follow-up
Ordinal Longitudinal Average multiplicative increase in the odds ratio of being in a
less versus more severe category across the follow-up period
Cox Proportional Hazards E6: Number of days to ﬁrst hospital
discharge
Time-to-Event Hazard ratio of time-to-hospital discharge
Accelerated Failure Time (Exponentiala and
Weibull distributions)
E6: Number of days to ﬁrst hospital
discharge
Time-to-Event Reduction in quantiles of time-to-hospital discharge
a Model was used in the analytic setting, displayed in Figs. 1 and 2.
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patients hospitalized with inﬂuenza at many of the same sites partici-
pating in FLU-IVIG [17,18]. As of September 1st, 2016, the responses of
the cohort study at randomization and across the follow-up period who
met the trial eligibility criteria are given in Table 2. We used these
longitudinal data to estimate category percentages for the placebo
group of our study. Table 3 gives the category percentages of the or-
dinal endpoint at day 7 for the placebo and IVIG groups under pro-
portional odds, as well as the ﬁve odds ratios for the ﬁve better versus
worse divisions of the ordinal endpoint. A demonstration of how to
derive the ﬁve odds ratios is included as a section at the end of this
paper.
For the simulation, we ﬁrst randomly sampled 320 patients from the
day 0 distribution of the cohort study to create day 0 data for both
groups (i.e., no treatment eﬀect at randomization). We generated
longitudinal data using a discrete-time Markov model whereby the day-
to-day transition probabilities for the placebo group were estimated
from the cohort study. For the treatment group, we varied on which
days and for which groups of patients (e.g., hospitalized or dead versus
discharged) the transition probabilities diﬀered from the placebo group.
Using a method from Peterson et al. [7], data were generated such that
the average odds ratio on day 7 for the ordinal endpoint approximated
1.77, the pre-speciﬁed value of FLU-IVIG. Additionally, we varied the
transition probabilities for the placebo group to simulate diﬀerent
target populations. Unlike the analytic setting, the proportional odds
assumption may not hold on day 7 and time-to-ﬁrst hospital discharge
may not be exponentially distributed. The supplementary material ex-
plains the data generating process in greater detail.
We ran 10,000 simulations of the clinical trial for each treatment
eﬀect and placebo group combination. For each simulated trial, we
ﬁtted the seven models to the corresponding six endpoints and com-
puted the corresponding Wald test statistics for the treatment eﬀect. For
each model, the empirical power is the proportion of the 10,000 si-
mulations for which the Wald test statistic meets signiﬁcance. Code to
run our simulation in the R programming language can be downloaded
from GitHub (https://github.com/RPeterson4/Comparative_FLU_IVIG_
Code).
3. Results
The results section is divided into two parts. First, we analytically
compare the ordinal endpoint evaluated at day 7 with the time-to-event
endpoint evaluated at days 7–14. Second, we compare the ordinal
endpoint by simulation to time-to-event, longitudinal, and binary
endpoints.
3.1. Analytic comparison of ordinal endpoint to time-to-event endpoint
Fig. 1 compares the power of the ordinal endpoint to the time-to-
event endpoint as a function of the granularity of the ordinal endpoint
(i.e., − ∑= q1 ‾i
k
i1
3), the number of days of follow-up for the time-to-event
endpoint, and the probability of discharge by day 7 in the placebo
group (p07). For ﬁxed p07, the time-to-event endpoint tends to perform
better with additional days of follow-up. For p07 values of 0.10 or lower
and 0.63 or higher, ordinal endpoints of high granularity with values of
0.9 or higher for − ∑= q1 ‾i
k
i1
3 have an almost universal advantage over
the time-to-event endpoint, including for the parameter values speciﬁed
in the power calculations of the FLU-IVIG trial. For p07 values ranging
from 0.20 to 0.50, longer follow-up periods (i.e., from 8 to 14 days)
grant the time-to-event endpoint a near universal advantage over the
ordinal endpoint.
Fig. 2 displays the right-center plot of Fig. 1 for FLU-IVIG but with
contours of power added to further clarify the diﬀerence in perfor-
mance between the time-to-event and ordinal endpoints. From day 7 to
day 14 of follow-up, the time-to-event endpoint gains about 10% power
over the ordinal endpoint. As the value of − ∑= q1 ‾i
k
i1
3 increases from
the lower bound of − +( )1 p p2 307 17 to the upper bound of 1, the ordinal
endpoint gains about 18% power over the time-to-event endpoint in
that span.
3.2. Simulation comparison of ordinal endpoint to other endpoints
We investigated seven diﬀerent treatment eﬀects each with diﬀerent
transition probabilities across the seven days of follow-up. Each treat-
ment eﬀect is deﬁned from days 1–7 of follow-up and arrives at an odds
ratio of 1.77 on day 7:
Table 2
FLU-IVIG placebo group distribution of the ordinal endpoint at randomization and across the 7 day follow-up period according to the cohort study [17,18].
Day of Evaluation Death ICU Hospitalized, not in ICU, on
oxygen
Hospitalized, not in ICU, not on
oxygen
Discharged, not back to normal
activities
Discharged, back to normal
activities
Day 0 (%)a 0 7.6 46.1 46.3 0 0
Day 1 (%) 0.2 6.4 40.9 43.1 8.1 1.2
Day 2 (%) 0.2 6.7 33.7 37.9 18.5 3.0
Day 3 (%) 0.2 6.7 28.8 33.0 23.2 8.1
Day 4 (%) 0.5 6.4 21.2 26.8 31.8 13.3
Day 5 (%) 0.5 5.9 19.2 21.9 33.3 19.2
Day 6 (%) 1.0 4.9 17.7 18.5 34.7 23.2
Day 7 (%) 1.0 4.9 16.3 14.5 36.2 27.1
a (%) percentage of patients in the placebo group for the given ordinal endpoint category.
Table 3
Distributions of the FLU-IVIG placebo group and IVIG group on day 7 of follow-up. The FLU-IVIG placebo group distribution was estimated from the cohort study
[17,18].
Death ICU Hospitalized, not in ICU, on
oxygen
Hospitalized, not in ICU, not on
oxygen
Discharged, not back to normal
activities
Discharged, back to normal
activities
% Placeboa 1.0 4.9 16.3 14.5 36.2 27.1
% IVIGb 0.6 2.9 10.4 10.8 35.6 39.7
Odds ratioc 1.77 1.77 1.77 1.77 1.77
a % Placebo: percentage of patients in the placebo group for the given ordinal endpoint category.
b % IVIG: percentage of patients in the IVIG group for the given ordinal endpoint category.
c Odds ratio: The odds of having the given ordinal endpoint category or less severe versus more severe between the IVIG and placebo groups.
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• T1: The treatment eﬀect remains constant for all categories across
each day of follow-up.
• T2: The treatment eﬀect only beneﬁts patients for days 1–3 for all
categories.
• T3: The treatment eﬀect constantly decreases with each day with no
additional beneﬁt on day 7 for all categories.
• T4: The treatment eﬀect remains constant across each day of follow-
up but is 33.3% more eﬀective for hospitalized patients on the log
odds ratio scale.
• T5: The treatment eﬀect only beneﬁts patients in the “ICU” and
“non-ICU, on oxygen categories” across each day of follow-up.
• T6: The treatment eﬀect only beneﬁts patients for days 5–7 for all
categories.
• T7: The treatment eﬀect constantly increases with each day, with
beneﬁt starting on day 2 for all categories.
We considered placebo group distributions corresponding to con-
sistently more or less underlying risk throughout the follow-up period:
• The FLU-IVIG placebo group distribution based on the cohort study
[17,18].
o Category percentages on day 7 from death to hospital discharge
with resumption of normal activities were: 1.0%, 4.9%, 16.3%,
14.5%, 36.2%, 27.1%.
• More severe placebo group (with more severe cases on each day of
follow-up).
o Category percentages on day 7 from death to hospital discharge
with resumption of normal activities were: 2.0%, 9.3% 28.0%,
19.2%, 27.2%, 14.3%.
• Less severe group (with fewer severe cases on each day of follow-
up).
o Category percentages on day 7 from death to hospital discharge
with resumption of normal activities were: 0.5%, 2.2%, 7.1%,
7.7%, 37.4%, 45.0%.
Supplementary Tables 1–3 display the respective placebo group
distributions on day 7 and their corresponding IVIG group distributions
for each treatment eﬀect.
Fig. 1. Comparison of the ordinal endpoint and time-to-event endpoint by follow-up period and − ∑= q1 ‾i
k
i1
3 according to their respective non-centrality parameters
which uniquely determine power. Plots are reproduced across diﬀerent probabilities of discharge by day 7 (p07) for the placebo group. The ordinal endpoint is
evaluated on day 7, while the time-to-event endpoint is evaluated across days 7–14. The blue region indicates that the ordinal endpoint yielded higher power, while
the red region indicates that the time-to-event endpoint yielded higher power. The purple dot in the right-center plot marks the value for FLU-IVIG. As we assume that
hospital discharge constitutes at least one category of the ordinal endpoint, the y-axes are bounded below by − +( )1 p p07 172 3. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 2. The right-center plot of Fig. 1 for FLU-IVIG with contours of power
added to indicate by how much either the ordinal endpoint or the time-to-event
endpoint surpassed the other in power. The blue region indicates that the or-
dinal endpoint yielded higher power, while the red region indicates that the
time-to-event endpoint yielded higher power. The purple dot marks the value
for FLU-IVIG. As we assume that hospital discharge constitutes at least one
category of the ordinal endpoint, the y-axis is bounded below by
− +( )1 p p07 172 3. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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Tables 4–6 give the estimated power for the six endpoints con-
sidered under diﬀerent treatment eﬀect scenarios and relative acuity in
the patient population. Supplementary Tables 4–6 give the average
coeﬃcient values corresponding to each power estimate (for how to
interpret each coeﬃcient estimate, see Table 1). For the proportional
odds model, adjusting for baseline health status (the bottom half of
each table) universally raised power by about 4–9% points across all
distributions of the placebo group and treatment eﬀect scenarios con-
sidered (see Tables 4–6). Across the three distributions of the placebo
group, only the Cox and AFT models assuming a Weibull distribution
yielded higher power for certain treatment eﬀects (i.e., T2–4) relative
to the proportional model, a ﬁnding that generally held with adjust-
ment for baseline health status. Both time-to-event endpoints yielded
low power under treatment eﬀects T6 and T7 which assume delay of
beneﬁt. Note that the overall proportion of patients discharged by day 7
under each treatment eﬀect scenario is relatively constant (see
Supplementary Tables 1–3), but the discharge times in the treatment
group diﬀer signiﬁcantly across scenarios. Overall, the Weibull AFT
model performed better than the exponential AFT model.
Excluding the Cox and AFT models, the proportional odds model
generally yielded the highest power across all treatment eﬀects and
distributions of the placebo group considered, including after adjust-
ment for baseline health status (see Tables 4–6). Moreover, the pro-
portional odds model with adjustment for baseline health status con-
sistently returned power close the pre-speciﬁed level of 80% or higher,
ranging from 79.94% to 91.66%. No other model was able to maintain
power at the desired level of 80% across all treatment eﬀects and pla-
cebo group distributions. However, for each treatment eﬀect under the
more severe placebo group distribution, the longitudinal ordinal out-
come and sliding dichotomy models generally yielded greater power
than the proportional odds model (see Table 5). These advantages
mostly failed to hold after adjustment for baseline health status. Across
all treatment eﬀects and placebo group distributions, the simple logistic
model and win ratio generally yielded lower power relative to the
proportional odds model including after adjustment for baseline health
status.
4. Discussion
To our knowledge, FLU-IVIG is the ﬁrst inﬂuenza trial to use an
ordinal scale of patient outcomes as the primary endpoint. A variation
of the ordinal scale is now being used by other inﬂuenza trials as a
primary or secondary endpoint [5,6]. Any novel endpoint should be
rigorously evaluated to address clinical and statistical concerns, espe-
cially one that makes use of a relatively uncommon data type like an
ordinal scale. In particular, a novel endpoint should be both inter-
pretable and able to more consistently detect a treatment eﬀect relative
to other endpoints that may be derived from the same information. In
that regard, we compared the power of the FLU-IVIG ordinal endpoint
to a time-to-event endpoint analytically and by simulation and to ﬁve
other endpoints by simulation. Selecting the most eﬃcient endpoint for
a trial includes weighing a number of clinical and statistical factors,
including the nature of the treatment eﬀect, length of the follow-up
period, and the target population's event rate of outcomes and grada-
tion and severity of patient illness. Our case study of the FLU-IVIG or-
dinal endpoint helps contextualize the relative importance of these
factors.
Provided that the hazard ratio remains constant over the follow-up
period, we demonstrated analytically that time-to-event endpoints as-
sessed over a longer follow-up period yield greater power than ordinal
endpoints when given moderate placebo group discharge probabilities
at the time the ordinal endpoint was assessed on day 7. With a high
number of placebo group patients on the cusp of hospital discharge on
day 7, we would expect the time-to-event endpoint to substantially
Table 4
Simulated power (%)a results for the FLU-IVIG placebo group on day 7 of follow-up (p07
b = 0.63).c
Model T1: Constant
beneﬁtd
T2: Beneﬁt only
for ﬁrst three
days
T3: Linear
decrease in
beneﬁt
T4: Larger beneﬁt for
hospitalized patients
T5: Beneﬁt only for
ICU and non-ICU, on
oxygen patients
T6: Beneﬁt only
for last three
days
T7: Linear
increase in
beneﬁt
No adjustment for baseline status
Simple Logistic 71.65 75.07 75.29 76.70 83.20 60.79 67.87
Sliding Dichotomy 69.55 78.04 75.71 74.81 93.04 59.11 64.11
Win Ratio 79.54 79.58 79.38 79.61 79.66 79.86 80.66
Proportional Odds 79.71 79.69 79.45 79.68 79.86 79.94 80.77
Longitudinal Ordinal
Outcome
82.98 71.52 77.96 83.35 67.21 79.45 84.59
Cox Proportional Hazards 76.73 96.46 92.66 81.92 87.47 36.39 53.81
Accelerated Failure Time
(Exponential)
68.43 94.24 89.17 74.72 81.44 27.45 42.49
Accelerated Failure Time
(Weibull)
78.83 96.64 93.62 83.78 88.55 37.09 55.83
Adjustment for baseline status
Simple Logistic 78.70 81.24 82.28 83.68 86.08 68.84 75.55
Sliding Dichotomy 71.96 79.82 77.92 77.49 93.29 61.88 67.09
Win Ratioe 83.67 82.90 82.59 83.94 72.09 86.26 86.14
Proportional Odds 86.25 86.50 85.95 86.50 87.26 86.93 86.70
Longitudinal Ordinal
Outcome
70.45 23.81 42.36 70.12 53.20 84.90 85.63
Cox Proportional Hazards 84.93 98.92 96.89 89.27 81.81 40.94 60.28
Accelerated Failure Time
(Exponential)
74.41 97.37 93.94 80.50 75.69 26.67 43.51
Accelerated Failure Time
(Weibull)
86.23 98.98 97.21 90.48 82.51 41.08 61.99
a Power (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the estimated treatment eﬀect of the ﬁtted model was signiﬁcant at
the two-sided 0.05 level. Power for the top three models for each treatment eﬀect with or without adjustment for baseline health status is printed in bold.
b p07 denotes the probability of discharge (i.e., categories 5 and 6 of the ordinal endpoint combined) by day 7 of follow-up for the placebo group.
c Supplementary Table 1 displays the category percentages for the FLU-IVIG placebo group on day 7 and each of the seven IVIG groups.
d Beneﬁt refers to the diﬀerences in transition probabilities between randomized groups across treatment eﬀects.
e Unlike all other models which include a covariate to adjust for baseline status, the win ratio stratiﬁes by only comparing patients who started at the same baseline
category between randomized groups.
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Table 5
Simulated power (%)a results for the more severe placebo group on day 7 of follow-up (p07
b = 0.42).c
Model T1: Constant
beneﬁtd
T2: Beneﬁt only
for ﬁrst three
days
T3: Linear
decrease in
beneﬁt
T4: Larger beneﬁt for
hospitalized patients
T5: Beneﬁt only for
ICU and non-ICU, on
oxygen patients
T6: Beneﬁt only
for last three
days
T7: Linear
increase in
beneﬁt
No adjustment for baseline status
Simple Logistic 82.12 80.31 81.22 83.64 65.36 80.66 82.11
Sliding Dichotomy 82.88 86.93 85.24 84.25 90.98 79.40 80.78
Win Ratio 80.85 81.52 80.71 81.15 80.61 81.28 81.04
Proportional Odds 80.97 81.59 80.89 81.31 80.77 81.43 81.21
Longitudinal Ordinal
Outcome
91.73 87.42 90.20 92.16 87.42 85.37 90.88
Cox Proportional Hazards 82.14 92.36 89.57 84.21 68.21 62.28 71.95
Accelerated Failure Time
(Exponential)
78.48 90.77 87.13 80.57 63.60 56.69 67.01
Accelerated Failure Time
(Weibull)
82.70 92.53 90.08 84.90 68.96 61.33 72.09
Adjustment for baseline status
Simple Logistic 87.82 85.40 86.69 88.66 69.21 86.46 87.88
Sliding Dichotomy 85.13 88.85 87.48 86.52 91.51 82.00 83.25
Win Ratioe 89.45 88.78 88.41 88.64 88.84 89.51 89.62
Proportional Odds 90.92 91.00 90.35 90.86 89.69 91.66 90.76
Longitudinal Ordinal
Outcome
84.67 49.41 65.97 84.07 82.32 92.25 92.45
Cox Proportional Hazards 88.46 96.79 94.64 90.08 64.76 66.60 77.72
Accelerated Failure Time
(Exponential)
83.84 95.45 92.43 86.31 60.35 57.61 70.32
Accelerated Failure Time
(Weibull)
88.92 96.85 94.92 90.61 65.07 65.65 77.73
a Power (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the estimated treatment eﬀect of the ﬁtted model was signiﬁcant at
the two-sided 0.05 level. Power for the top three models for each treatment eﬀect with or without adjustment for baseline health status is printed in bold.
b p07 denotes the probability of discharge (i.e., categories 5 and 6 of the ordinal endpoint combined) by day 7 of follow-up for the placebo group.
c Supplementary Table 2 displays the category percentages for the more severe placebo group on day 7 and each of the seven IVIG groups.
d Beneﬁt refers to the diﬀerences in transition probabilities between randomized groups across treatment eﬀects.
e Unlike all other models which include a covariate to adjust for baseline status, the win ratio stratiﬁes by only comparing patients who started at the same baseline
category between randomized groups.
Table 6
Simulated power (%)a results for the less severe placebo group on day 7 of follow-up (p07
b = 0.82).c
Model T1: Constant
beneﬁtd
T2: Beneﬁt only for
ﬁrst three days
T3: Linear decrease
in beneﬁt
T4: Larger beneﬁt for
hospitalized patients
T6: Beneﬁt only for
last three days
T7: Linear increase
in beneﬁt
No adjustment for baseline status
Simple Logistic 54.07 63.20 63.42 62.44 36.23 45.35
Sliding Dichotomy 47.75 58.77 56.92 55.50 32.77 39.06
Win Ratio 75.87 76.15 76.16 76.08 76.09 75.59
Proportional Odds 75.90 76.20 76.16 76.13 76.11 75.63
Longitudinal Ordinal Outcome 64.44 44.81 52.52 62.78 65.88 70.26
Cox Proportional Hazards 70.74 99.04 95.81 80.04 15.94 31.88
Accelerated Failure Time
(Exponential)
55.18 97.11 90.71 66.84 7.51 17.25
Accelerated Failure Time
(Weibull)
75.21 99.11 96.52 83.48 18.67 37.27
Adjustment for baseline status
Simple Logistic 59.39 68.44 69.06 68.29 41.08 50.68
Sliding Dichotomy 49.97 60.64 58.93 57.89 34.40 41.08
Win Ratioe 73.82 72.61 72.31 73.28 77.76 75.46
Proportional Odds 80.52 81.15 80.80 80.68 80.12 79.94
Longitudinal Ordinal Outcome 45.15 6.13 14.09 40.69 71.35 70.70
Cox Proportional Hazards 79.02 99.79 98.50 87.80 17.60 37.29
Accelerated Failure Time
(Exponential)
58.68 98.82 94.48 70.81 5.83 16.23
Accelerated Failure Time
(Weibull)
82.50 99.79 98.80 90.09 20.03 41.97
Due to the skewness of the less severe placebo group distribution, a treatment eﬀect corresponding to T5 that approximated an odds ratio of 1.77 on day 7 could not
be found.
a Power (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the estimated treatment eﬀect of the ﬁtted model was signiﬁcant at
the two-sided 0.05 level. Power for the top three models for each treatment eﬀect with or without adjustment for baseline health status is printed in bold.
b p07 denotes the probability of discharge (i.e., categories 5 and 6 of the ordinal endpoint combined) by day 7 of follow-up for the placebo group.
c Supplementary Table 3 displays the category percentages for the less severe placebo group on day 7 and each of the six IVIG groups.
d Beneﬁt refers to the diﬀerences in transition probabilities between randomized groups across treatment eﬀects.
e Unlike all other models which include a covariate to adjust for baseline status, the win ratio stratiﬁes by only comparing patients who started at the same baseline
category between randomized groups.
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improve in power with follow-up periods of longer than 7 days which
provide more time for events (i.e., hospital discharge) to occur.
Conversely, with high discharge probabilities on day 7 and hence more
patients who have already had the event in the placebo group, we
would expect longer follow-up periods to only marginally beneﬁt the
time-to-event endpoint. Similarly, with very low discharge probabilities
on day 7, very few patients would be close to leaving the hospital in the
placebo group. Follow-up periods beyond 14 days would then be re-
quired to raise the power of the time-to-event endpoint above the or-
dinal endpoint. If trial designers expect a fairly ill target population and
can assume that the treatment eﬀect will be constant over a prolonged
period, time-to-event endpoints may be preferable.
Of course, a constant treatment eﬀect may not be reasonable to
assume. Our simulation study gives insight into the types of endpoints
that may provide the highestpower under plausible expressions of a
non-constant treatment eﬀect. Regardless of the underlying risk in the
placebo group, for treatment eﬀects T2–4, the Cox and Weibull AFT
models generally returned larger power relative to the proportional
odds model with or without adjustment for baseline health status. This
is likely because treatment eﬀects T2–4 assume disproportionate ben-
eﬁt soon after randomization or to hospitalized patients to reduce time-
to-hospital discharge. Conversely, when the treatment eﬀect was de-
layed as in T6 and T7, the time-to-event endpoints performed relatively
poorly. This is likely because treatment eﬀects T6 and T7 fail to dis-
charge patients from the hospital early on in follow-up. In terms of
consistency, the proportional odds model with adjustment for baseline
health status was the only model to return power at the pre-speciﬁed
level or higher across all treatment eﬀect and placebo group combi-
nations.
Alternatively, the ordinal endpoint evaluated on day 7 could be
dichotomized into a binary endpoint but with the potential caveat of a
loss of information. To that end, more complex binary endpoints have
been proposed. For the purposes of our study, neither the win ratio,
which compares ordinal endpoint category on day 7, nor the sliding
dichotomy, which compares the change in patient health status be-
tween baseline and day 7, consistently improved power relative to the
ordinal endpoint.
The win ratio without adjustment for baseline health status was
always less than half a percentage point below the proportional odds
model in power. With adjustment for baseline health status, the win
ratio was often within a few percentage points of the proportional odds
model. The gap may have widened because unlike all other models in
this paper which include a covariate to adjust for baseline health status,
the win ratio stratiﬁes by only comparing patients who started at the
same baseline category between randomized groups. This may have
resulted in a number of ties in patient improvement to weaken increases
in power. Overall, the win ratio closely tracked the proportional odds
model in power and without adjustment for baseline health status may
be preferable given its ease of interpretation relative to the odds ratio
from ﬁtting a proportional odds model.
In addition, longitudinal endpoints may perform better than end-
points assessed at a single time point. Yet, we found that the long-
itudinal ordinal outcome model was less powerful than evaluating the
ordinal endpoint at a single time point, except when enrolling a target
population with many hospitalized patients (i.e., the more severe pla-
cebo group). This may be because the longitudinal ordinal outcome
model studied assumes a constant treatment eﬀect over time, an erro-
neous assumption given our data generating mechanism in the simu-
lation setting. Additionally, test statistics other than the Wald test sta-
tistic of the day by treatment group interaction may be more powerful.
In the simulation setting, our analysis found that adjusting for
baseline health status universally increased power across all treatment
eﬀect and placebo group combinations for the proportional odds model,
and for many of the other models. Analyses which include an adjust-
ment for baseline health status should be considered even if the primary
endpoint is not an ordinal endpoint.
Previous research has used Markov models to investigate infectious
disease data in other areas including HIV [19,20]. In our case study of a
severe inﬂuenza trial, we constructed transition matrices based oﬀ an
ordinal endpoint to analytically derive placebo and IVIG groups with
treatment eﬀects that each approximated the pre-speciﬁed value of
FLU-IVIG. Previous research has generally compared the proportional
odds model to other models by ﬁtting them to retrospective data [21].
Our simulation scheme provides a framework for how such data may be
generated.
Our study is mainly limited by its speciﬁcity to the six-level ordinal
endpoint and the type of target population considered in the FLU-IVIG
trial. Of course, ordinal endpoints can be re-deﬁned to better ﬁt the
target population. For example, if the FLU-IVIG ordinal endpoint were
to be used for a more severely ill target population, the ICU category
could be divided according to whether mechanical ventilation is re-
quired and the two hospital discharge categories could be combined.
Additionally, in an unblinded study, the discharge categories as well as
the oxygen categories could be combined due to their dependence on
subjective clinician/patient assessments. Though diﬀerent ordinal
endpoints have been used in trials of vascular disease, S. pneumoniae
infection, and traumatic brain injury [21–24], our ﬁndings in the
analytic setting and our general approach to evaluating the FLU-IVIG
ordinal endpoint are applicable to those ordinal endpoints and others.
Overall, our ﬁndings suggest that ordinal endpoints with high
granularity can reliably exceed time-to-event endpoints in power for
hospitalized inﬂuenza populations in which most patients will naturally
progress to hospital discharge by the time of endpoint assessment, si-
milar to the FLU-IVIG trial. Furthermore, we ﬁnd that the FLU-IVIG
ordinal endpoint can perform even better after adjusting for baseline
health status. However, if only 20–50% of patients will be discharged
from the hospital by the end of the follow-up period, leaving many on
the cusp of discharge, a time-to-event endpoint with a longer follow-up
period may be more eﬃcient. Additionally, a time-to-event endpoint
may be able to more reliably detect a treatment eﬀect that is strongest
in the ﬁrst few days following randomization.
More broadly, when deciding between an ordinal endpoint and a
time-to-event endpoint, important factors to consider for each are the
granularity of the ordinal endpoint and the follow-up period of the
time-to-event endpoint. Categories which contain the largest propor-
tions of patients should be divided as evenly as possible; conversely,
categories which contain the fewest patients should be collapsed into
categories with greater numbers. For the time-event endpoint, longer
follow-up periods should be weighed to allow more time for events to
occur. Moreover, longer follow-up periods and trials that cannot be
blinded may not be ideal for ordinal endpoints that rely on patients to
report information, like the two discharged categories in the FLU-IVIG
ordinal endpoint. Concentrating on these two factors –granularity and
follow-up period– in addition to the target population should help trial
designers choose between ordinal endpoints and time-to-event end-
points for trials in severe inﬂuenza and other disease areas.
Although the choice of an ordinal outcome as the primary endpoint
may be uncommon in clinical trials, our ﬁndings from this paper along
with our previous paper and others provide strong support for the ro-
bustness of an ordinal endpoint to detect a treatment eﬀect in trials of
severe inﬂuenza [7,21–24]. The data type of an ordinal scale with its
multiple qualitative categories should not be discouraging to trial de-
signers; rather, if an ordinal scale is to be considered, factors that may
inﬂuence its clinical relevance and power should be thoroughly in-
vestigated.
Derivation of the ﬁve odds ratios
Under the proportional odds assumption of the model, the odds
ratio of having a given category or less severe versus more severe for
any binary split of the ordinal endpoint is ﬁxed at 1.77. For example, for
the binary split of discharged, back to normal activities versus
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discharged, not back to normal activities or worse, the odds ratio can be
derived as:
−
−
=39.7/(1 39.7)
27.1/(1 27.1)
1.77
Similarly, for the binary split of discharged versus not discharged or
dead, the odds ratio can be derived as:
+ − −
+ − −
=(39.7 35.6/(1 39.7 35.6)
(27.1 36.2)/(1 27.1 36.2)
1.77
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